Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ming-tao HU"'
Autor:
Lin Qi, Jie-ying Liang, Zhong-wu Li, Shao-yan Xi, Yu-ni Lai, Feng Gao, Xian-rui Zhang, De-shen Wang, Ming-tao Hu, Yi Cao, Li-jian Xu, Ronald C.K. Chan, Bao-cai Xing, Xin Wang, Yu-hong Li
Publikováno v:
iScience, Vol 26, Iss 10, Pp 107702- (2023)
Summary: Histopathological images of colorectal liver metastases (CRLM) contain rich morphometric information that may predict patients’ outcomes. However, to our knowledge, no study has reported any practical deep learning framework based on the h
Externí odkaz:
https://doaj.org/article/c8d3833bb8cc4a3398c7f127be17b06d
Autor:
Wei Wang, Liu-Fang Ye, Hua Bao, Ming-Tao Hu, Ming Han, Hai-Meng Tang, Chao Ren, Xue Wu, Yang Shao, Feng-Hua Wang, Zhi-Wei Zhou, Yu-Hong Li, Rui-Hua Xu, De-Shen Wang
Publikováno v:
Gastric Cancer. 25:1017-1030
Background Tumour immune microenvironment heterogeneity is prevalent in numerous cancers and can negatively impact immunotherapy response. Immune heterogeneity and evolution in gastroesophageal adenocarcinoma (GEA) have not been studied in the past.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ea0cc30f15023a36df5592053784900
https://doi.org/10.1007/s10120-022-01324-7
https://doi.org/10.1007/s10120-022-01324-7
Publikováno v:
Journal of Fuel Chemistry and Technology. 50:366-375
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9507d192e0830d738b746939e5bf0c7c
https://doi.org/10.1016/s1872-5813(21)60160-3
https://doi.org/10.1016/s1872-5813(21)60160-3
Autor:
Zhi Qiang Wang, Hui Yang, Long Bai, Fenghua Wang, Yu Hong Li, Ming-Tao Hu, Jie-Ying Liang, Chao Ren, Rui-Hua Xu, Liu-Fang Ye, De Shen Wang
Publikováno v:
Investigational New Drugs. 39:836-845
Background Gemcitabine plus cisplatin is regarded as the standard first-line therapy for patients with advanced biliary tract cancer (BTC); however, no standard chemotherapy has yet been recommended after treatment failure. Modified FOLFIRINOX (mFOLF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f40d2a0ce240c969755afc37c303bd7
https://doi.org/10.1007/s10637-020-01045-7
https://doi.org/10.1007/s10637-020-01045-7
Autor:
Hui Yang, Yuan-Chao Zheng, Xiao-Yun Liu, De Shen Wang, William Pat Fong, Yun Zheng, Zhizhong Pan, Rui-Hua Xu, Yunfei Yuan, Yun Wang, Zhi-gang Chen, Lele Song, Yu Hong Li, Binkui Li, Gong Chen, Ming-Tao Hu
Publikováno v:
Theranostics
Rationale: Hepatectomy and adjuvant chemotherapy after resection of colorectal liver metastases (CRLM) may improve survival, however, patients which may benefit cannot currently be identified. Postoperative circulating tumor DNA (ctDNA) analysis can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87d7239eefd4f23830ce31e42948d24b
https://doi.org/10.7150/thno.59644
https://doi.org/10.7150/thno.59644
Autor:
Liu-Fang Ye, Zi-Yao Huang, Xiao-Xi Chen, Zhi-Gang Chen, Si-Xian Wu, Chao Ren, Ming-Tao Hu, Hua Bao, Ying Jin, Feng Wang, Feng-Hua Wang, Zi-Ming Du, Xue Wu, Huai-Qiang Ju, Yang Shao, Yu-Hong Li, Rui-Hua Xu, De-Shen Wang
Publikováno v:
Drug Resistance Updates. 65:100883
This study aimed to identify mechanisms of drug resistance to the combination of vemurafenib, irinotecan, and cetuximab (VIC) in BRAFForty-one patients with BRAFBRAF mutant in baseline plasma and its dynamics are significantly associated with VIC-rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aff546b40a554bd5816a44bea5f89ff9
https://doi.org/10.1016/j.drup.2022.100883
https://doi.org/10.1016/j.drup.2022.100883
Autor:
De Shen Wang, William Pat Fong, Hui Yang, Lei Fan, Ming-Tao Hu, Zhi-gang Chen, Mayan Huang, Xiuxing Chen, Rui-Hua Xu, Jie-Ying Liang, Yu Hong Li, Yun Wang, Ziming Du
Publikováno v:
Cancer immunology, immunotherapy : CIIReference:s. 71(3)
Exosomal PD-L1 (exoPD-L1) could induce immunosuppression functionally, thus impairing patients’ survival in melanoma, NSCLC, and gastric cancer. However, no evidence demonstrates the feasibility of circulating exoPD-L1 and soluble PD-L1 (sPD-L1) as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::471786b08dab3b91417d6bd030824679
https://pubmed.ncbi.nlm.nih.gov/34322779
https://pubmed.ncbi.nlm.nih.gov/34322779
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Liu-Fang, Ye, Chao, Ren, Long, Bai, Jie-Ying, Liang, Ming-Tao, Hu, Hui, Yang, Zhi-Qiang, Wang, Feng-Hua, Wang, Rui-Hua, Xu, Yu-Hong, Li, De-Shen, Wang
Publikováno v:
Investigational new drugs. 39(3)
Background Gemcitabine plus cisplatin is regarded as the standard first-line therapy for patients with advanced biliary tract cancer (BTC); however, no standard chemotherapy has yet been recommended after treatment failure. Modified FOLFIRINOX (mFOLF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0decc8ffd90013fddd48e4fb44b49cc6
https://pubmed.ncbi.nlm.nih.gov/33411209
https://pubmed.ncbi.nlm.nih.gov/33411209
Autor:
William Pat Fong, Ling Yun Wang, Yun Wang, Yu Hong Li, Ming-Tao Hu, Jie-Ying Liang, Zhi-gang Chen
Publikováno v:
International Immunopharmacology. 98:107890
Pancreatic Ductal Adenocarcinoma (PDAC) is characterized by an extensive and dense fibrous stroma, which plays an active role in tumor growth and metastasis. Despite the growing importance of the tumor microenvironment in PDAC prognosis, the immune c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::211bdd0b7a046a6dab4bb8c30f926a46
https://doi.org/10.1016/j.intimp.2021.107890
https://doi.org/10.1016/j.intimp.2021.107890